Veiled Therapeutics

Veil Therapeutics (also referred to as Veiled Therapeutics) is a biotechnology company developing a next-generation polymer platform designed to overcome the immunogenicity limitations of biologic drugs. The company's proprietary Veil Platform restructures traditional PEG polymer repeats into a high-density, non-immunogenic bottlebrush architecture (POEGMA) that forms a dense hydration shield around therapeutics, extending half-life and improving stability without triggering an immune response. Veil's lead program, VTx-101, is a polymer-conjugated uricase in pre-clinical development for the treatment of chronic refractory gout. The platform has validated applications across proteins, peptides, lipid nanoparticles (LNPs), and aptamers, offering a versatile solution for stealth drug delivery.